INT123564

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2004
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 13
Total Number 14
Disease Relevance 9.61
Pain Relevance 3.58

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Rock2) cytoskeleton (Rock2) nucleus (Rock2)
kinase activity (Rock2) microtubule organizing center (Rock2) cytoplasm (Rock2)
Anatomy Link Frequency
dorsal 1
CNS 1
Rock2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
antagonist 48 100.00 Very High Very High Very High
intrathecal 2 99.74 Very High Very High Very High
Antinociceptive 4 99.38 Very High Very High Very High
Inflammation 19 99.24 Very High Very High Very High
Analgesic 2 99.08 Very High Very High Very High
Cold hyperalgesia 8 98.28 Very High Very High Very High
Arthritis 10 97.92 Very High Very High Very High
dorsal rhizotomy 10 97.32 Very High Very High Very High
Central nervous system 39 97.16 Very High Very High Very High
Deafferentation 2 95.16 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypoxia 22 99.58 Very High Very High Very High
Pulmonary Hypertension 450 99.24 Very High Very High Very High
INFLAMMATION 29 99.24 Very High Very High Very High
Glioma 6 99.24 Very High Very High Very High
Increased Venous Pressure Under Development 51 98.18 Very High Very High Very High
Hypertension 70 98.12 Very High Very High Very High
Hyperalgesia 9 98.08 Very High Very High Very High
Arthritis 10 97.92 Very High Very High Very High
Erectile Dysfunction 148 97.56 Very High Very High Very High
Diabetes Mellitus 56 97.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ca(2+) sensitization induced by phenylephrine, norepinephrine and carbachol was markedly antagonized by all three ROK inhibitors.
Negative_regulation (inhibitors) of ROK
1) Confidence 0.59 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15857612 Disease Relevance 0 Pain Relevance 0.11
In addition, the contractile response to KCl-induced depolarization was highly sensitive to these ROK inhibitors.
Negative_regulation (inhibitors) of ROK
2) Confidence 0.43 Published 2005 Journal Biochem. Pharmacol. Section Abstract Doc Link 15857612 Disease Relevance 0 Pain Relevance 0.12
Both ROCKI and ROCKII are inhibited by fasudil with IC50 values of 0.26 ?
Negative_regulation (inhibited) of ROCKII
3) Confidence 0.42 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2500253 Disease Relevance 0.20 Pain Relevance 0.11
Antinociceptive effects of AS1892802, a novel Rho kinase inhibitor, in rat models of inflammatory and noninflammatory arthritis.
Negative_regulation (inhibitor) of Rho kinase associated with inflammation, antinociceptive and arthritis
4) Confidence 0.32 Published 2010 Journal J. Pharmacol. Exp. Ther. Section Title Doc Link 20534789 Disease Relevance 1.18 Pain Relevance 1.07
One week after septuple rhizotomy, administration of intrathecal Y-27632, an antagonist of Rho-kinase (ROCK), increased the density of both fiber types over vehicle-treated controls.
Negative_regulation (antagonist) of Rho-kinase associated with antagonist and intrathecal
5) Confidence 0.28 Published 2004 Journal J. Neurosci. Section Abstract Doc Link 15574730 Disease Relevance 0.59 Pain Relevance 0.98
Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy.
Negative_regulation (inhibition) of Rho-kinase in dorsal associated with hyperalgesia, cold hyperalgesia and dorsal rhizotomy
6) Confidence 0.28 Published 2004 Journal J. Neurosci. Section Title Doc Link 15574730 Disease Relevance 0.32 Pain Relevance 0.69
The IL-6 release was significantly suppressed by Y-27632 and fasudil, Rho-kinase inhibitors.
Negative_regulation (inhibitors) of Rho-kinase
7) Confidence 0.17 Published 2009 Journal Neurochem. Int. Section Abstract Doc Link 19427347 Disease Relevance 0.49 Pain Relevance 0
Therefore, Rho-kinase inhibitor may be considered to be a new clinical candidate for the treatment of CNS disorders in addition to cerebral vasospasms.
Negative_regulation (inhibitor) of Rho-kinase in CNS associated with central nervous system and increased venous pressure under development
8) Confidence 0.17 Published 2009 Journal Neurochem. Int. Section Abstract Doc Link 19427347 Disease Relevance 0.97 Pain Relevance 0.34
Long-term inhibition of Rho-kinase, an effector of the small GTPase Rho, ameliorated MCT-induced PAH in rats and hypoxia-induced PAH in mice.
Negative_regulation (inhibition) of Rho-kinase associated with pulmonary hypertension and hypoxia
9) Confidence 0.06 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.13 Pain Relevance 0
Human clinical trials have recently been performed using SAR407899, a Rho-kinase inhibitor four times more potent than fasudil, for the treatment of mild to moderate ED (Rhoket trials—Aventis).
Negative_regulation (inhibitor) of Rho-kinase associated with erectile dysfunction
10) Confidence 0.05 Published 2010 Journal Advances in Pharmacological Sciences Section Body Doc Link PMC2997760 Disease Relevance 1.28 Pain Relevance 0
Vasodilation of arteries in the corpora is largely responsible for mediating the erectile process, and inhibition of the calcium sensitization pathway with Rho-kinase inhibitors offers a therapeutic option for the treatment of ED that does not involve the direct targeting of the NO/sGC/cGMP pathway.
Negative_regulation (inhibition) of Rho-kinase associated with erectile dysfunction and increased venous pressure under development
11) Confidence 0.05 Published 2010 Journal Advances in Pharmacological Sciences Section Body Doc Link PMC2997760 Disease Relevance 0.20 Pain Relevance 0.03
In chronicly hypoxic rats, inhalation of Rho-kinase inhibitors nearly normalized PAH, but had no pulmonary vascular selectivity [15].

2.1.6.

Negative_regulation (inhibitors) of Rho-kinase associated with pulmonary hypertension and hypoxia
12) Confidence 0.04 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.25 Pain Relevance 0
mg/kg) and were subsequently treated without or with a Rho-kinase inhibitor (fasudil, 30?
Negative_regulation (inhibitor) of Rho-kinase
13) Confidence 0.04 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 1.08 Pain Relevance 0.07
In animal models, Fasudil, a Rho-kinase inhibitor, showed promising results in the treatment of pulmonary hypertension.
Negative_regulation (inhibitor) of Rho-kinase associated with hypertension
14) Confidence 0.01 Published 2009 Journal Pediatr Surg Int Section Body Doc Link PMC2734260 Disease Relevance 0.92 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox